Price Alert

Sangamo Therapeutics Inc. (SGMO)

NASDAQ: SGMO · Real-Time Price · USD

0.66

0.03 (4.23%)

At close: Sep 26, 2025, 3:59 PM

0.66

0.09%

After-hours: Sep 26, 2025, 07:57 PM EDT

Sangamo Therapeutics Statistics

Share Statistics

Sangamo Therapeutics has 301.71M shares outstanding. The number of shares has increased by 17.86% in one year.

Shares Outstanding	301.71M
Shares Change (YoY)	17.86%
Shares Change (QoQ)	9.21%
Owned by Institutions (%)	23.86%
Shares Floating	295.14M
Failed to Deliver (FTD) Shares	111,097
FTD / Avg. Volume	1.9%

Short Selling Information

The latest short interest is 17.68M, so 5.86% of the outstanding shares have been sold short.

Short Interest	17.68M
Short % of Shares Out	5.86%
Short % of Float	5.91%
Short Ratio (days to cover)	4.24

Valuation Ratios

The PE ratio is -2.1 and the forward PE ratio is -2.16. Sangamo Therapeutics's PEG ratio is 0.03.

PE Ratio	-2.1
Forward PE	-2.16
PS Ratio	3.56
Forward PS	4.2
PB Ratio	9.04
P/FCF Ratio	-3.05
PEG Ratio	0.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Sangamo Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.13, with a Debt / Equity ratio of 1.34.

Current Ratio	1.13
Quick Ratio	1.13
Debt / Equity	1.34
Debt / EBITDA	-0.34
Debt / FCF	-0.45
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$315.85K
Profits Per Employee	$-535.2K
Employee Count	183
Asset Turnover	0.57
Inventory Turnover	n/a

Taxes

Income Tax	-167K
Effective Tax Rate	0.17%

Stock Price Statistics

The stock price has increased by -23.88% in the last 52 weeks. The beta is 1.21, so Sangamo Therapeutics's price volatility has been higher than the market average.

Beta	1.21
52-Week Price Change	-23.88%
50-Day Moving Average	0.54
200-Day Moving Average	0.85
Relative Strength Index (RSI)	70.53
Average Volume (20 Days)	5,837,407

Income Statement

In the last 12 months, Sangamo Therapeutics had revenue of 57.8M and earned -97.94M in profits. Earnings per share was -0.49.

Revenue	57.8M
Gross Profit	57.8M
Operating Income	-103.97M
Net Income	-97.94M
EBITDA	-89.09M
EBIT	-98.45M
Earnings Per Share (EPS)	-0.49

Full Income Statement

Balance Sheet

The company has 41.92M in cash and 30.57M in debt, giving a net cash position of 11.35M.

Cash & Cash Equivalents	41.92M
Total Debt	30.57M
Net Cash	11.35M
Retained Earnings	-1.5B
Total Assets	97.56M
Working Capital	2.23M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -67.14M and capital expenditures -267K, giving a free cash flow of -67.41M.

Operating Cash Flow	-67.14M
Capital Expenditures	-267K
Free Cash Flow	-67.41M
FCF Per Share	-0.33

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -179.88% and -169.45%.

Gross Margin	100%
Operating Margin	-179.88%
Pretax Margin	-169.74%
Profit Margin	-169.45%
EBITDA Margin	-154.13%
EBIT Margin	-179.88%
FCF Margin	-116.62%

Dividends & Yields

SGMO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for SGMO is $3, which is 354.5% higher than the current price. The consensus rating is "Buy".

Price Target	$3
Price Target Difference	354.5%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-22.35
Piotroski F-Score	4